S. 4875, Pharmaceutical Subsidy with Public-Health Framing. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
S. 4875 · Mixed
What it does
This bill creates a federal contract program to pay pharmaceutical companies $75–$300 million per year for developing new antibiotics that treat drug-resistant infections. Companies apply after FDA approval, and the government pays them annually for up to 10 years, with payments reduced by any sales revenue they earn. The bill also funds hospital stewardship programs and surveillance of antibiotic resistance.
The analysis names pharmaceutical companies developing antimicrobial drugs — and 2 more groups — among the beneficiaries.
The trade-off
Annual payments are reduced only by actual US sales revenue, not by R&D costs or manufacturing expenses—companies can receive full subsidies even if they earn substantial profit margins on the same drug.
The analysis put a high warning level on this bill. Transparency scores 62%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Michael Bennet. Cosponsored by John Hickenlooper, Kirsten Gillibrand, Mike Rounds and Todd Young.